Grateful to @theNCI for this opportunity to expand @UMGCCC and @umms participation in NCTN trials—advancing research and expanding access for our patients! @ASTRO_org @NRGonc @teekayowo

We are so glad to have 4 outstanding new residents join our department as PGY-2s! Welcome Anita Nwiloh, Paul Armstrong, Christian Clark, & Felly Jean-Koleoso @Dr_O_Kay. We look forward to learning & growing with you over the next 4 years & beyond.

Congrats to this year’s #radonc medical resident grads! Colleagues celebrated during graduation dinner, where certificates & diplomas were awarded & outstanding accomplishments celebrated. Left to right: Drs. Hua-Ren Ryan Cherng @hrcherng, Soha Bazyar @SohaBazyar & James Assif.

Congratulations to faculty members Dr. Mark Mishra @MarkMishraMD on receiving ARRO Educator of the Year & Dr. Junliang Xu for his Dr. Karl Prado Physics Educator of the Year Award! Thank you both for your dedication to teaching.

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? @NRGonc @ASTRO_org #BreastCancer https://t.co/ISD7HOd5q7

#ASCO25 MR-guided FUS + TMZ OS ↑ (36.4 vs 19.1 mo) & ↑ PFS in HGG vs matched controls in Phase 1/2 trial. BB barrier opened safely in 100% of cases; cfDNA tracked disease. Promising noninvasive platform for targeted delivery @UMGCCC @UMDNsgyChair https://t.co/m7wsl0DKoL

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗

#ASCO25 Final CATNON trial results confirm: adjuvant TMZ (not concurrent) improves OS in IDH-mut anaplastic glioma (12.5 yrs vs 1.7 yrs in IDHwt). No added benefit from concurrent TMZ. RT→adjTMZ remains standard for IDHmt, 1p/19q-intact disease #btsm 🔗

#ASCO25: In Phase III KEYNOTE-630, adjuvant pembrolizumab after surgery+RT in high-risk LA cSCC did not significantly improve RFS vs placebo (HR 0.76, p=0.072). More TRAEs with pembro (64% vs 41%). Trial stopped early for futility. #radonc 🔗

#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc 🔗

#ASCO25: In COG ACNS1123, children with NGGCT treated with proton vs. photon WVRT had significantly better long-term IQ outcomes. First prospective data showing protons preserve cognition in pediatric brain RT. Photon RT linked to IQ decline over time. 🔗

#ASCO25 Phase III SWOG/@NRGonc S1914 trial shows adding atezolizumab to SBRT in early-stage NSCLC did not improve OS or PFS. More grade ≥3 AEs & local failures seen with IO+SBRT vs SBRT . First major phase III to test this combo—results are cautionary 🔗

#ASCO25 PROs from OUTBACK (N=919) show adding adjuvant chemo to CRT in LACC ↑ toxicity (e.g neuropathy) without OS gain. Long-term issues—sexual dysfunction, fatigue, pain—persisted through year 3. Survivorship care in #radonc must address unmet needs. 🔗

#ASCO25: CAN-2409, a gene therapy that induces immunogenic tumor cell death, cut recurrence/death risk by 30% (HR 0.7, p=0.0155) in int/high-risk localized prostate cancer when added to RT±ADT. 80% path CR vs 63.6% with SoC. Low added toxicity. #radonc 🔗

Putting the brightest inquisitive minds together to find cures for cancer @MayoClinicNeuro @MayoClinic @MayoCancerCare @HopkinsNsurg @HopkinsEngineer @JohnsHopkins @uminn @UMBaltimore @KKLabJHU #washDC @paosmeade @HugoGuerreroLab @Honggangcui @MayoInvents Inspiring

Consensus Radiation Treatment Planning Guidelines Utilizing (68)Ga-DOTATATE PET/CT for Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics- Fantastic work led by ⁦@HaleyPerlow⁩ ⁦@joshuapalmermd⁩

In this new #RedJournal article from @MarkMishraMD @hrcherng et al, read about an exploratory analysis of the conditional neurocognitive function failure risk in patients receiving whole brain radiotherapy for brain metastases in NRG Oncology CC001. https://t.co/M159oslkNA

⚡️Today FDA approved Vorasidenib for IDH-mutant low grade gliomas When patients ask you about this drug, make sure to inform them that ▶️ risk of tumor progression at 2 years is 49% with Vorasidenib (INDIGO trial) compared to 15% with chemoRT (RTOG 9802) ▶️tumors remain stable

Congratulations to Dr. Hua-Ren (Ryan) Cherng @hrcherng on winning the department Medical Resident Article of the Year for "Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001”. Well done, Dr. Cherng!

Congratulations to this year’s residency program graduates, Drs. Jie Ding, Rebecca Krc @KrcRebecca & Bansi Savla @SavlaBansi! Best of luck in your careers, we know that each of you will make outstanding contributions to the field of #radonc & patient care. #residency